Section Arrow
GMAB.NASDAQ
- Genmab A/S ADS
Quotes are at least 15-min delayed:2025/06/03 23:11 EDT
Last
 21.35
-0.42 (-1.93%)
Day High 
21.525 
Prev. Close
21.77 
1-M High
21.94 
Volume 
1.13M 
Bid
21.26
Ask
22
Day Low
20.88 
Open
21.125 
1-M Low
18.885 
Market Cap 
13.41B 
Currency USD 
P/E 12.77 
%Yield -- 
10-SMA 20.94 
20-SMA 20.43 
50-SMA 19.96 
52-W High 28.96 
52-W Low 17.235 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
1.70/45.20
Enterprise Value
13.54B
Balance Sheet
Book Value Per Share
8.60
Cash Flow
Cash Flow Yield
0.08
Income Statement
Total Revenue
21.53B
Operating Revenue Per Share
3.91
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0598+0.0218+57.37%-- 
RENBRenovaro0.288-0.0019-0.66%-- 
BMEABiomea Fusion2.49+0.94+60.65%-- 
TRAWTraws Pharma Inc1.87+0.45+31.69%-- 
REVBRevelation Biosciences Inc0.9007+0.0777+9.44%-- 
Quotes are at least 15-min delayed:2025/06/03 23:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.